Enlivex Therapeutics Ltd. — Investor Relations & Filings
Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-28 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-27 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-18 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-15 | English | |
| 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-04-21 | English | |
| 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-04-08 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47859677 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-28 | English | ||
| 47518294 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-27 | English | ||
| 46384758 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-18 | English | ||
| 46362365 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-05-15 | English | ||
| 34766214 | 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-04-21 | English | ||
| 33814097 | 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-04-08 | English | ||
| 33048678 | 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-03-26 | English | ||
| 33040031 | 20-F - Enlivex Ltd. (0001596812) (Filer) | 2026-03-25 | English | ||
| 33040001 | 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-03-25 | English | ||
| 33032354 | 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-03-24 | English | ||
| 33013111 | 6-K - Enlivex Ltd. (0001596812) (Filer) | 2026-03-23 | English | ||
| 33001982 | 424B3 - Enlivex Ltd. (0001596812) (Filer) | 2026-03-20 | English | ||
| 19423449 | 6-K - Enlivex Therapeutics Ltd. (0001596812) (Filer) | 2026-02-10 | English | ||
| 30804306 | 6-K Filing | 2026-02-05 | English | ||
| 30804284 | 6-K Filing | 2026-01-26 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Enlivex Therapeutics Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34882/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34882 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34882 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34882 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34882}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Enlivex Therapeutics Ltd. (id: 34882)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.